• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fresenius Kabi has a Class I Ivenix infusion pump recall

January 12, 2024 By Sean Whooley

Fresenius Kabi Ivenix infusion system
The Ivenix infusion system. [Image courtesy of Fresenius Kabi]
The FDA determined that a recall of the Fresenius Kabi Ivenix large-volume infusion pump is Class I, the most serious kind.

This recall affects the LVP-0004 model of the Ivenix large-volume pumps. Fresenius Kabi distributed these systems between Oct. 1, 2021, and July 31, 2023. In total, the company recalled 938 devices in the U.S. since initiating the recall on Nov. 29, 2023.

Fresenius Kabi reports no injuries or deaths related to the recall, according to the FDA.

The company recalled the pump because some units have mechanical issues with the fluid valve pins. This issue may cause the pins — located inside the pump’s internal housing — to not move properly. Instead of going where they should, the pins could impact the side of a sensor.

When this occurs, the system detects the failure and sets off an alarm, stopping an infusion if in progress and preventing the pump from working. The failure may also be detected during pump setup, which can cause a delay in starting treatment.

Using the affected pumps could lead to underdosing, interruption in therapy or delay in therapy. These could all lead to serious harm or death.

Fresenius Kabi’s Ivenix large-volume pump is one of three primary components of the Ivenix Infusion System. The pump uses air pressure to precisely control the flow of fluids to patients in hospitals and outpatient centers. It only has compatibility with specific sterile, single-use, disposable administration sets.

Fresenius Kabi suggested that affected customers increase their clinical monitoring if the pump is being used to deliver life-sustaining medications. They should use a different pump if the pump exhibits the issue during setup. Users should also remove pumps that exhibit a problem alarm during use.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance Tagged With: FDA, Fresenius Kabi, freseniuskabi

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS